BRÈVE

sur Enteralia Bioscience S.r.l

Enteralia Bioscience Acquires TFarma, Expands in Italy's Nutraceutical Market

Enteralia Bioscience SRL has announced the acquisition of TFarma, a company specializing in nutraceuticals and medical devices in Italy. This move marks a significant step in Enteralia's expansion within the Italian market, a key sector in Europe.

The acquisition brings Enteralia access to TFarma's network of over 20 medical representatives, particularly skilled in gynecology and gastroenterology. Integrating TFarma's strong product portfolio is expected to enhance Enteralia's growth.

Enteralia is also set to expand its sales network, underpinned by new products from Nemysis Limited, its parent company. These efforts aim to boost revenue and profits significantly.

Enteralia plans to invest in TFarma's team, acknowledging their importance in the company's continued success. The shared focus on women's health and gastroenterology underscores Enteralia's strategy for future growth.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Enteralia Bioscience S.r.l